Select Transactions

Acquisition of
generics business of
$1.05 billion
June 2017
Mallinckrodt Pharmaceuticals
Sale of
Intrathecal business to
$203 million
March 2017
Assembly Biosciences
Microbiome partnership with
$2.6 billion
($50 million upfront)
January 2017
HealthCare Royalty Partners
acquisition financing
for undisclosed
spec pharma
$100 million
February 2016
Torreya is a leading strategic M&A advisor to global life sciences companies.   MORE
Torreya is one of the most active financial advisors on pharmaceutical-product asset sales.   MORE
Torreya’s Capital Markets team arranges debt financings, royalty monetizations, IPOs, and private equity recapitalizations.   MORE
Torreya is a leading advisor on pre-commercial and commercial-stage licensing deals.   MORE
Torreya's 10-year anniversary

As we mark our 10-year anniversary, Torreya emerges as a leading advisor in global life sciences transactions.

See Activity Update

1 Capital IQ and Torreya calculations: September 2017